What is Alector?
Founded in 2013 and headquartered in South San Francisco, California, Alector is dedicated to the research and preventative development of treatments for neurodegenerative diseases affecting elderly populations. The company's scientific endeavors encompass a range of debilitating conditions, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Alector's strategic focus on the underlying biology of these diseases aims to create novel therapeutic approaches that could potentially halt or reverse disease progression, addressing a critical unmet need in geriatric medicine and neurology.
How much funding has Alector raised?
Alector has raised a total of $430.5M across 6 funding rounds:
Series C
$32M
Series D
$29.5M
Series E
$133M
Stock Offering
$176M
Debt
$50M
Debt
$10M
Series C (2015): $32M with participation from Topspin Partners, GV, OrbiMed, Polaris Partners, MRL Ventures Fund, and Mission Bay Capital
Series D (2016): $29.5M led by Dementia Discovery Fund, Amgen Business Development, and AbbVie
Series E (2018): $133M supported by New Leaf Venture Partners, OrbiMed, MRL Ventures, Section 32, GV, AbbVie Ventures, Perceptive Advisors, the Dementia Discovery Fund, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, Federated Kaufmann Fund, Polaris Partners, Amgen Business Development, Deerfield, Mission Bay Capital, and Casdin Capital
Stock Issuance/Offering (2019): $176M, investors not publicly disclosed
Debt (2024): $50M backed by Hercules Capital
Debt (2024): $10M with participation from Hercules Capital
Key Investors in Alector
New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm specializing in early-stage investments within the life sciences sector, focusing on companies that develop innovative therapeutics and diagnostics.
OrbiMed
OrbiMed is a global investment firm dedicated to the healthcare sector, providing capital and strategic support to companies across biopharmaceuticals, medical devices, and healthcare services.
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology and life sciences, backing visionary entrepreneurs and transformative companies.
What's next for Alector?
With substantial backing from major enterprise-level funding rounds and a recent strategic investment, Alector is poised for an accelerated phase of development and expansion. The company's commitment to tackling complex neurodegenerative diseases suggests a strategic focus on advancing its preclinical and clinical programs. Future endeavors will likely involve further investment in R&D, potential strategic partnerships with larger pharmaceutical entities, and the scaling of its operational capabilities to support its pipeline. The sustained capital flow indicates a strong belief in Alector's long-term vision and its potential to deliver breakthrough therapies in a field with significant therapeutic gaps.
See full Alector company page
